85 related articles for article (PubMed ID: 22773158)
1. Oncology in vivo data integration for hypothesis generation.
Wei J; Chen M
J Integr Bioinform; 2012 Jul; 9(2):193. PubMed ID: 22773158
[TBL] [Abstract][Full Text] [Related]
2. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
Gabrielsson J; Green AR
J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
[TBL] [Abstract][Full Text] [Related]
3. A Linux cluster for population pharmacokinetic analyses.
Speth H
Int J Clin Pharmacol Ther; 2004 Mar; 42(3):189-90. PubMed ID: 15049442
[No Abstract] [Full Text] [Related]
4. Making every SAR point count: the development of Chemistry Connect for the large-scale integration of structure and bioactivity data.
Muresan S; Petrov P; Southan C; Kjellberg MJ; Kogej T; Tyrchan C; Varkonyi P; Xie PH
Drug Discov Today; 2011 Dec; 16(23-24):1019-30. PubMed ID: 22024215
[TBL] [Abstract][Full Text] [Related]
5. The challenge of selecting the 'right' in vivo oncology pharmacology model.
Firestone B
Curr Opin Pharmacol; 2010 Aug; 10(4):391-6. PubMed ID: 20634135
[TBL] [Abstract][Full Text] [Related]
6. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
Gabrielsson J; Dolgos H; Gillberg PG; Bredberg U; Benthem B; Duker G
Drug Discov Today; 2009 Apr; 14(7-8):358-72. PubMed ID: 19162219
[TBL] [Abstract][Full Text] [Related]
7. Data warehouse implementation with clinical pharmacokinetic/pharmacodynamic data.
Koprowski SP; Barrett JS
Int J Clin Pharmacol Ther; 2002 Mar; 40(3):S14-29. PubMed ID: 11911606
[TBL] [Abstract][Full Text] [Related]
8. Integration of genomic data for pharmacology and toxicology using Internet resources.
Paananen J; Wong G
SAR QSAR Environ Res; 2006 Feb; 17(1):25-36. PubMed ID: 16513550
[TBL] [Abstract][Full Text] [Related]
9. Drug development in oncology: a regulatory perspective.
Augustus S
Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790
[TBL] [Abstract][Full Text] [Related]
10. Development of a chemotherapy regimen interaction database for the mobile internet: detecting interactions with psychotropics through OncoRx-MI.
Yap KY; Chui WK; Chan A;
Inform Health Soc Care; 2011 Sep; 36(3):132-46. PubMed ID: 21848450
[TBL] [Abstract][Full Text] [Related]
11. TopFit: a PC-based pharmacokinetic/pharmacodynamic data analysis program.
Tanswell P; Koup J
Int J Clin Pharmacol Ther Toxicol; 1993 Oct; 31(10):514-20. PubMed ID: 8262691
[TBL] [Abstract][Full Text] [Related]
12. An in vivo database model for pharmacological and physiological dosage for experimental animals.
Gunes A; Ozturk Y; Babanli A
Comput Biol Med; 2009 Jul; 39(7):590-4. PubMed ID: 19423091
[TBL] [Abstract][Full Text] [Related]
13. Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development.
Agoram BM; Demin O
Drug Discov Today; 2011 Dec; 16(23-24):1031-6. PubMed ID: 22020181
[TBL] [Abstract][Full Text] [Related]
14. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R.
Comets E; Brendel K; Mentré F
Comput Methods Programs Biomed; 2008 May; 90(2):154-66. PubMed ID: 18215437
[TBL] [Abstract][Full Text] [Related]
15. Beyond data integration.
Slater T; Bouton C; Huang ES
Drug Discov Today; 2008 Jul; 13(13-14):584-9. PubMed ID: 18598913
[TBL] [Abstract][Full Text] [Related]
16. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
17. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
[TBL] [Abstract][Full Text] [Related]
18. Dunn's index for cluster tendency assessment of pharmacological data sets.
Rivera-Borroto OM; Rabassa-Gutiérrez M; Grau-Ábalo Rdel C; Marrero-Ponce Y; García-de la Vega JM
Can J Physiol Pharmacol; 2012 Apr; 90(4):425-33. PubMed ID: 22443093
[TBL] [Abstract][Full Text] [Related]
19. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
Kuhlmann J
Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
[TBL] [Abstract][Full Text] [Related]
20. The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development.
Yu XQ; Wilson AG
Future Med Chem; 2010 Jun; 2(6):923-8. PubMed ID: 21426110
[No Abstract] [Full Text] [Related]
[Next] [New Search]
